肝胆相照论坛

标题: 乙型肝炎病毒的S基因突变和抗HBs亚型非特异性导致HBsAg和抗HB [打印本页]
作者: StephenW    时间: 2017-2-16 22:14     标题: 乙型肝炎病毒的S基因突变和抗HBs亚型非特异性导致HBsAg和抗HB

J Med Virol. 2017 Feb 15. doi: 10.1002/jmv.24782. [Epub ahead of print]
Mutation in the S gene of hepatitis B virus and anti-HBs subtype-nonspecificity contributed to the coexistence of HBsAg and anti-HBs in patients with chronic hepatitis B virus infection.Fu X1,2,3, Chen J1,3, Chen H1,3, Lin J1,3, Xun Z1,2,3, Li S1,2,3, Liu C1,3, Zeng Y1,3, Chen T1,3, Yang B1,3, Ou Q1,3.
Author information


AbstractThe mechanism for the coexistence of hepatitis B surface antigen (HBsAg) and antibodies to HBsAg (anti-HBs) in chronic HBV infected patients remains controversial. This study aimed to explore the role of HBV S gene mutation and anti-HBs subtype-nonspecificity in patients with simultaneous HBsAg/anti-HBs positivity. Chronic HBV infections with (n = 145, group I) and without (n = 141, group II) anti-HBs were included. The S gene was amplified and sequenced. The neutralization experiment was used in group I patients' sera to determine the specificity of anti-HBs. Additionally, the HBV vaccinated persons' sera were used to estimate the neutralize capacity of anti-HBs against HBsAg in group I patients. Results showed that 2.63% (145/5513) chronic HBV infected patients had positive results for anti-HBs. HBsAg amino acid (aa) substitution rate in 35 patients of group I was significantly higher than that in 58 patients of group II (1.89% vs. 0.95%, P < 0.05), especially within 'a' determinant (4.05% vs. 1.22%, P < 0.05). In group I patients, anti-HBs in (74.29%, 26/35) patients was not directed to the subtypes of the co-existing HBsAg. Besides, some HBsAg variations in group I patients, sG145R mutation, inserted mutations and continuous aa mutations within the major hydrophilic region (MHR), decreased the neutralized capacity of anti-HBs from HBV vaccinated persons. In conclusion, both of HBsAg mutation and anti-HBs subtype-nonspecificity contributed to the coexistence of HBsAg and anti-HBs in chronic HBV infection. HBV vaccine recipients may still have a risk of HBV infection when exposure to patients with simultaneous HBsAg/anti-HBs positivity. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.



KEYWORDS: antibodies to HBsAg; coexistence; hepatitis B surface antigen; mutation; serotype

PMID:28198078DOI:10.1002/jmv.24782
作者: StephenW    时间: 2017-2-16 22:15

J Med Virol。 2017年2月15日。doi：10.1002 / jmv.24782。 [印刷前电子版]
乙型肝炎病毒的S基因突变和抗HBs亚型非特异性导致HBsAg和抗HBs在慢性乙型肝炎病毒感染患者中的共存。
Fu X1,2,3，Chen J1,3，Chen H1,3，Lin J1,3，Xun Z1,2,3，Li S1,2,3，Liu C1,3，Zeng Y1,3，Chen T1,3 ，Yang B1,3，Ou Q1,3。
作者信息

    福建医科大学附属第一医院实验医学科。
    2福建医科大学第一临床学院，福州。
    福建医科大学第一附属医院遗传诊断实验室，中国。

抽象

在慢性HBV感染患者中乙型肝炎表面抗原（HBsAg）和HBsAg抗体（抗HBs）共存的机制仍有争议。本研究旨在探讨HBV S基因突变和抗HBs亚型非特异性在同时HBsAg /抗HBs阳性患者中的作用。包括（n = 145，I组）和无（n = 141，II组）抗HB的慢性HBV感染。扩增S基因并测序。中和实验用于I组患者的血清以确定抗HBs的特异性。此外，HBV免疫人血清用于评估抗HBs对I组患者中HBsAg的中和能力。结果显示，2.63％（145/5513）慢性HBV感染患者的抗HBs阳性结果。第一组35例患者的HBsAg氨基酸（aa）替代率显着高于第二组58例患者（1.89％vs. 0.95％，P <0.05），尤其是在“a”决定因素（4.05％vs. 1.22 ％，P <0.05）。在I组患者中，（74.29％，26/35）患者中的抗HBs不针对共存的HBsAg的亚型。此外，第一组患者的一些HBsAg变异，sG145R突变，主要亲水区（MHR）内的插入突变和连续aa突变降低了来自HBV接种人的抗HBs的中和能力。总之，HBsAg突变和抗HBs亚型非特异性有助于HBsAg和抗HBs在慢性HBV感染的共存。 HBV疫苗接种者在暴露于同时HBsAg /抗HBs阳性的患者时仍然具有HBV感染的风险。本文受版权保护。版权所有。

本文受版权保护。版权所有。
关键词：

抗HBsAg抗体;共存乙型肝炎表面抗原;突变;血清型

PMID：
    28198078
DOI：
    10.1002 / jmv.24782



欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5